MedTrace Logo

GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

NCT06490341 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-07-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the regimen of gemcitabine, cisplatin combined with nimotuzumab and sintilimab works to treat locally advanced nasopharyngeal carcinoma before chemoradiotherapy. It will also learn about the safety of the regimen. The main questions it aims to answer are:

* Does the regimen increase the number of participants who has a significant tumor shrinkage?
* What medical problems do participants have when taking the regimen? Researchers will evaluate the safety and efficacy of the regimen.

Participants will:

* Take the regimen every 21 days, for twice.
* Visit the clinic weekly for drug administration, checkups and tests.
* Keep a diary of their symptoms.

Conditions

  • Locally Advanced Nasopharyngeal Carcinoma

Interventions

DRUG

GP Regimen, Nimotuzumab, Sintilimab

gemcitabine,ciplatin, nimotuzumab, sintilimab

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • He Xiaohui · Cancer Hospital, CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-20
Primary Completion
2026-07-20
Completion
2027-07-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490341 on ClinicalTrials.gov